Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Capital Employed: 2025

Historic Return on Capital Employed for Silence Therapeutics (SLN) over the last 2 years, with Sep 2025 value amounting to 0.14%.

  • Silence Therapeutics' Return on Capital Employed was N/A to 0.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.14%, marking a year-over-year change of. This contributed to the annual value of 0.44% for FY2024, which is N/A change from last year.
  • Per Silence Therapeutics' latest filing, its Return on Capital Employed stood at 0.14% for Q3 2025, which was up 27.82% from 0.19% recorded in Q2 2025.
  • Silence Therapeutics' Return on Capital Employed's 5-year high stood at 0.14% during Q3 2025, with a 5-year trough of 0.40% in Q1 2024.